Fidelity Investments
IMRX icon

Fidelity Investments’s Immuneering IMRX Stock Holding History

Fidelity Investments’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51.1M Buy
9,697,938
+12,443
+0.1% +$63.8K ﹤0.01% 1434
2025
Q4 		$63.7M Buy
9,685,495
+898,443
+10% +$5.77M ﹤0.01% 1342
2025
Q3 		$61.5M Buy
8,787,052
+8,566,052
+3,876% +$44.5M ﹤0.01% 1365
2025
Q2 		$745K Buy
+221,000
New +$379K ﹤0.01% 2825
2024
Q3 		– Sell
-6,743
Closed -$8.63K – 5611
2024
Q2 		$8.63K Sell
6,743
-226,455
-97% -$372K ﹤0.01% 4386
2024
Q1 		$674K Sell
233,198
-256,249
-52% -$1.44M ﹤0.01% 2628
2023
Q4 		$3.6M Sell
489,447
-122,721
-20% -$818K ﹤0.01% 2156
2023
Q3 		$4.7M Sell
612,168
-46,276
-7% -$425K ﹤0.01% 2063
2023
Q2 		$6.68M Buy
658,444
+255,923
+64% +$2.46M ﹤0.01% 1983
2023
Q1 		$3.91M Buy
402,521
+249,458
+163% +$1.42M ﹤0.01% 2169
2022
Q4 		$742K Sell
153,063
-69,951
-31% -$620K ﹤0.01% 2614
2022
Q3 		$3.19M Sell
223,014
-140
-0.1% -$1.11K ﹤0.01% 2295
2022
Q2 		$1.21M Buy
223,154
+9,632
+5% +$51.4K ﹤0.01% 2628
2022
Q1 		$1.38M Buy
213,522
+131,818
+161% +$1.27M ﹤0.01% 2701
2021
Q4 		$1.32M Sell
81,704
-168,296
-67% -$4.1M ﹤0.01% 2637
2021
Q3 		$6.64M Buy
+250,000
New +$6.72M ﹤0.01% 2280

Other funds holding IMRX

S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Fidelity Investments's IMRX Position: Q1 2026 in Review

Fidelity Investments increased its Immuneering (IMRX) stake by 0.13% in Q1 2026, buying an estimated $63.8K and bringing the position to 9,697,938 shares worth $51.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1434.

Fidelity Investments first reported a position in IMRX in Q3 2021 and has held it in 16 quarters since. The position peaked at $63.7M in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Fidelity Investments held 9,697,938 shares of Immuneering worth $51.1M as of Q1 2026.
  • Fidelity Investments bought 12,443 Immuneering shares in Q1 2026, an estimated $63.8K.
  • Immuneering made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #1434 holding.
  • Fidelity Investments first reported a position in Immuneering in Q3 2021 and has held it in 16 quarters since.
  • Fidelity Investments's Immuneering position peaked at $63.7M in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.